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Sittiporn Pattaradilokrat, Sandra J. Cheesman, Richard Carter*
Ashworth Laboratories, Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United
Kingdom
Protective immunity against blood infections of malaria is partly specific to the genotype, or strain, of the parasites. The target
antigens of Strain Specific Protective Immunity are expected, therefore, to be antigenically and genetically distinct in different
lines of parasite. Here we describe the use of a genetic approach, Linkage Group Selection, to locate the target(s) of Strain
Specific Protective Immunity in the rodent malaria parasite Plasmodium chabaudi chabaudi. In a previous such analysis using
the progeny of a genetic cross between P. c. chabaudi lines AS-pyr1 and CB, a location on P. c. chabaudi chromosome 8
containing the gene for merozoite surface protein-1, a known candidate antigen for Strain Specific Protective Immunity, was
strongly selected. P. c. chabaudi apical membrane antigen-1, another candidate for Strain Specific Protective Immunity, could
not have been evaluated in this cross as AS-pyr1 and CB are identical within the cell surface domain of this protein. Here we
use Linkage Group Selection analysis of Strain Specific Protective Immunity in a cross between P. c. chabaudi lines CB-pyr10
and AJ, in which merozoite surface protein-1 and apical membrane antigen-1 are both genetically distinct. In this analysis
strain specific immune selection acted strongly on the region of P. c. chabaudi chromosome 8 encoding merozoite surface
protein-1 and, less strongly, on the P. c. chabaudi chromosome 9 region encoding apical membrane antigen-1. The evidence
from these two independent studies indicates that Strain Specific Protective Immunity in P. c. chabaudi in mice is mainly
determined by a narrow region of the P. c. chabaudi genome containing the gene for the P. c. chabaudi merozoite surface
protein-1 protein. Other regions, including that containing the gene for P. c. chabaudi apical membrane antigen-1, may be
more weakly associated with Strain Specific Protective Immunity in these parasites.
Citation: Pattaradilokrat S, Cheesman SJ, Carter R (2007) Linkage Group Selection: Towards Identifying Genes Controlling Strain Specific Protective
Immunity in Malaria. PLoS ONE 2(9): e857. doi:10.1371/journal.pone.0000857
INTRODUCTION
In regions of the world where malaria is endemic, anti-parasitic
protective immunity against infection with the pathogenic blood
stages of the parasites is acquired gradually after repeated
exposure to malaria [1–3]. This immunity is non-sterile, leading
to a state of premunition in which low parasite densities are
maintained in the host without causing disease symptoms. In
contrast to the slow acquisition of protective immunity to malaria
under natural conditions, such immunity can be achieved
relatively quickly in humans under controlled clinical conditions
and in laboratory animals after one, or a few, blood stage-induced
infections with a single cloned strain (genotype) of malaria
parasites followed by drug cure [4–10]. However, while this
immunity can be very effective in protecting individuals against
blood stage malarial infection with parasites of the same genotype,
it is often less effective against challenge infection with blood stage
parasites of a different genotype. These observations imply the
existence of Strain Specific Protective Immunity (SSPI) in malaria.
Thus, the slow acquisition of immunity to naturally acquired
malarial infection is likely to be at least partly due to the existence
of polymorphism in the target antigens of protective immunity
against the parasites (i.e. multiple allelic forms of an antigen-
coding gene) [11].
Natural populations of human malaria parasites [12–16] and
laboratory strains of rodent malaria parasites [17,18] are, indeed,
genetically highly polymorphic. Molecular characterisation of
genes for protein antigens expressed on the surface of merozoites
during blood stage malarial infection has revealed extensive
sequence polymorphism in many of these antigen-coding genes.
Prominent amongst them are genes encoding the merozoite
surface protein-1 (MSP-1) [19,20] and the apical membrane
antigen-1 (AMA-1) [21,22]. Both MSP-1 and AMA-1 have been
implicated as targets of SSPI in Plasmodium falciparum malaria in
humans [23–28] and in Plasmodium chabaudi malaria in rodents
[29–31].
In a previous study using Linkage Group Selection (LGS) [9] to
search for genes encoding targets of SSPI in P. chabaudi chabaudi,w e
located a region of the genome on P. c. chabaudi chromosome 8
which contains the gene for MSP-1 [9] as encoding a major target
of SSPI. However, the two P. c. chabaudi strains, AS-pyr1 and CB,
used in that study are genetically identical for the cell-surface,
ectodomain region of the gene for AMA-1 (Cheesman and Carter,
unpublished data), the other prominent candidate for SSPI in
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analysis could have detected AMA-1 as a target of SSPI [9]. In the
present study, we have conducted LGS analysis of SSPI on two P.
c. chabaudi strains, AJ and CB-pyr10, which are genetically different
for the genes for both MSP-1 and AMA-1 (Cheesman and Carter,
unpublished data). The present analysis has again identified the
region on P. c. chabaudi chromosome 8 containing the gene for
MSP-1 to be under strong SSPI selection. A weaker SSPI response
was also found in the region on P. c. chabaudi chromosome 9
containing the gene for AMA-1. However, no region in the
genome of P. c. chabaudi was identified under strength of SSPI
selection comparable to that on the region containing the gene for
MSP-1. The combined results from these two studies indicate,
therefore, that the main force of SSPI is determined by the single,
narrow region of the P. c. chabaudi genome containing the gene for
the protein antigen MSP-1.
RESULTS
Characterisation of Strain Specific Protective
Immunity in mice for Plasmodium chabaudi
chabaudi cloned strains CB and AJ
Immunity against the blood stages of P. c. chabaudi was induced in
groups of female CBA mice, five to six weeks old on first infection,
by two successive single strain blood stage-induced infections of
either P. c. chabaudi CB or AJ, drug cured with mefloquine of, as
described in Materials and Methods. Sixteen weeks after the last
mefloquine dose, two CB-immunised mice and two AJ-immunised
mice were challenged with a mixture of an equal proportion of
blood stage parasites of CB and AJ. A non-immune mouse, which
was a batch mate of the immunised mice, was inoculated with the
same mixture of blood stage parasites of CB and AJ. Total
parasitaemias were measured daily by microscopic analysis of thin
blood smears (Figure 1A). The proportions of parasites carrying
the CB or AJ alleles of P. c. chabaudi msp-1 were determined using
strain specific Real Time Quantitative-Polymerase Chain Re-
action (RTQ-PCR) analysis of DNA samples obtained from the
mixed strain infections between 5 and 8 days after inoculation (see
Materials and Methods).
In mice previously immunised with either CB or AJ, the total
parasitaemias following challenge with the mixed strain infections
of P. c. chabaudi CB and AJ were greatly reduced relative to the
total parasitaemia in a non-immune batch mate infected with the
same mixture (Figure 1A). It is clear, therefore, that a strain-
transcending immunity must have been present in the CB and AJ
immunised mice as both reduced the absolute parasitaemias to
a similar degree. Parasitaemias of the strain homologous to the
immunising one were, however, consistently lower, and the
parasites were eliminated more rapidly, than those of the
heterologous strain in the immunised mice (Figure 1C and 1D).
By contrast, CB and AJ were present in almost equal proportions
throughout the period of observation in the non-immune mouse
(days 5 to 8) (Figure 1B).
The differential effect in the strain specifically immunised mice
was greatest on day 7 of infection when parasites of the
homologous strain were undetectable (,1% parasitaemia) by
strain specific RTQ-PCR (see Materials and Methods), while parasites
of the heterologous strain survived at parasitaemias of ,6% and
1–3% in CB- and AJ-immunised mice, respectively (Figure 1C and
1D). Single strain (CB or AJ) immunised batch mates of the mice
tested in this experiment were used to apply SSPI selection
pressure against the uncloned progeny of a genetic cross between
CB and AJ, as described in the following section.
Strain Specific Protective Immune Selection of the
Uncloned Cross Progeny between P. c. chabaudi
Cloned Strains CB and AJ
A genetic cross between P. c. chabaudi CB and AJ was generated
(see Materials and Methods) and yielded a predicted maximum
number of independent recombinant lines of approximately 3,800
(Table 1), as described in Materials and Methods. Sporozoites were
harvested from the mosquitoes containing the cross and inoculated
into non-immune mice as uncloned cross progeny (see Materials and
Methods). The blood stage parasites of the uncloned cross progeny
were subinoculated into mice which had been immunised with one
or the other of the parental strains. A non-immune mouse, which
was a batch mate of the immunised mice, was inoculated with the
same mixture of the uncloned CB x AJ cross progeny. The
uncloned cross progeny was allowed to grow in the CB- and AJ-
immunised mice and in the non-immune batch mate (Figure 2).
The blood stage parasites in the CB- and AJ-immunised mice were
harvested and expanded by subinoculation of 10
6 parasitised Red
Blood Cells (pRBC) into groups of four non-immune female CBA
mice on days 11 and 12 of infection, respectively. The cross
progeny from the non-immune mouse was similarly expanded by
subinoculation on day 9 of infection. These parasites were
prepared for extraction of parasite genomic DNA for the
subsequent analysis, as described in Materials and Methods.
Molecular Genetic Analysis of SSPI Selected
Uncloned Cross Progeny
The genomic DNA of parasites derived from the CB- and AJ-
immune selected cross progeny and from the cross progeny grown
in the control non-immunised batch mate was typed with genome-
wide quantitative genetic markers produced by Amplified
Fragment Length Polymorphism (AFLP) [32] (see Materials and
Methods). From 97 combinations of selective AFLP primers, 350
polymorphic bands that differentiated CB and AJ strains of P. c.
chabaudi were obtained. Of these bands, 197 were present only in
AJ and 153 were present only in CB. These were used as AFLP
markers for the strains AJ and CB, respectively. The Comparative
Intensity (CI) (see Materials and Methods for a definition) [9] was
calculated for each AFLP marker in the CB- and AJ-immune
selected cross progeny.
Following AJ-specific immune selection, 24 of the 197 AFLP
markers for strain AJ (AJ markers) (12.2% of AJ specific markers)
had CIs of less than 50% under AJ-specific immune selection (i.e.
intensity reduction of greater than 50% relative to growth of the
cross progeny in the non-immune batch mate), listed in Table 2.
These AJ markers under SSPI selection were sequenced, as
described in Materials and Methods. 19 contained a single sequence
each, all of which were identified in the P. c. chabaudi genome
database, at the website http://www.sanger.ac.uk/cgi-bin/blast/
submitblast/p_chabaudi. The predicted orthologous loci of these
P. c. chabaudi contigs were, thereafter, located within the P.
falciparum genome. Because of the high level of conserved synteny
between the genomes of P. falciparum and the rodent malaria
parasites [33], the chromosomal locations of the P. falciparum
orthologues of AJ markers could, in turn, be mapped to the
equivalent predicted chromosomal positions in the P. c. chabaudi
genome. The remaining 5 AJ markers under SSPI selection gave
unreadable sequence data. Their physical locations in the P. c.
chabaudi genome could not be determined (Table 2).
Of the 19 AJ markers whose predicted orthologues were
successfully identified in the P. falciparum genome, one mapped to
a region on P. falciparum chromosome 4 which is syntenic with
Targets of Malaria Immunity
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were located to a region on P. falciparum chromosome 9 which is
syntenic with one on P. c. chabaudi chromosome 8. Three markers
were located to a region on P. falciparum chromosome 11 which is
syntenic with one on P. c. chabaudi chromosome 9. Five additional
markers were located to a region on P. falciparum chromosome 12
which is syntenic with one on chromosome 14 of P. c. chabaudi.A
final marker responding to SSPI selection was located to a region
on P. falciparum chromosome 14 corresponding to one on P. c.
chabaudi chromosome 12 (Table 2).
In addition, 92 of the 197 AJ markers were located onto ten P. c.
chabaudi chromosomes and six unassigned P. c. chabaudi linkage
groups of a P. c. chabaudi genetic linkage map previously generated
from the progeny of a genetic cross between AS and AJ strains
[34]. The genetic position of the 92 markers is displayed versus its
CI in Figure 3. 21 AJ markers with CIs of ,50% following AJ-
specific immune selection successfully mapped onto three P. c.
chabaudi chromosomes and two unassigned P. c. chabaudi linkage
groups (Table 2). In most cases, the location of the markers by
genetic mapping was in agreement with that of the physical
mapping. However, five markers that were located to P .c. chabaudi
chromosome 14 by physical mapping mapped genetically to P. c.
chabaudi chromosome 7. The reason for this discrepancy is not
known and will require further investigation. Four markers whose
orthologues could not be identified in P. falciparum were genetically
located to unassigned P. c. chabaudi linkage groups g2 (one marker)
and g12 (three markers).
The six AJ markers with the greatest reduction in intensity (CI
of below 20%) following the AJ-specific immune selection were all
Figure 1. Mixed strain infections of Plasmodium chabaudi chabaudi CB and AJ in mice pre-immunised with either strain, or in a non-immune
batch mate. (A) shows total parasitaemias during the course of mixed strain infections in immunised and non-immune mice as measured by
microscopic examination of thin blood smears stained with Giemsa’s stain: non-immune mouse (dotted line with open circles), two CB-immunised
mice (dashed lines with filled symbols), two AJ-immunised mice (unbroken lines with filled symbols). Strain specific parasitaemias (AJ in pink; CB in
green) are shown (B) in the non-immune mouse, (C) in the two CB-immunised mice and (D) in the two AJ-immunised mice. The strain specific
parasitaemias in the mixed strain infections were calculated from the total parasitaemias measured on thin blood smears stained with Giemsa’s stain
and from the proportions of CB and AJ parasites in the mixtures as determined using strain specific RTQ-PCR (see text). Squares and triangles
represent mouse 1 and 2, respectively, in the CB and AJ immunised mice in Fig. 1A, C and D.
doi:10.1371/journal.pone.0000857.g001
Figure 2. Course of blood stage induced infection of the uncloned CB
x AJ cross progeny grown in a non-immune mouse (dotted line with
open circles), in a CB-immunised mouse (pink line filled squares) and
in an AJ-immunised mouse (blue line with filled symbols). Arrows
indicate day of infection when the uncloned cross progeny grown in
the immunised mice or the non-immune mouse were sub-inoculated
for expansion in non-immune mice (see text).
doi:10.1371/journal.pone.0000857.g002
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genetic mapping (represented in bold in Table 2). These AJ
markers generally decreased in CI with deceasing physical distance
(P. falciparum) or genetic distance (P. c. chabaudi) from the AJ allele
of the P. c. chabaudi msp-1 locus (Table 2, Figure 3). The pro-
portion of parasite DNA carrying the AJ allele of msp-1 was
reduced to undetectable levels (,1%) as measured by strain
specific RTQ-PCR in the cross progeny grown under the AJ-
specific immune selection compared to its presence at a pro-
portion of 60.0% in the cross progeny grown in the non-
immune mouse (Table 2, Figure 3). Thus, the P. c. chabaudi
msp-1 locus lies at the lowest point that has been detected in the
strain specific immunity-selected valley on P. c. chabaudi chromo-
some 8.
Table 1. The parameters used to calculate the predicted maximum number of recombinant lines present in the pooled progeny of
the genetic cross between strains CB-pyr10 and AJ of Plasmodium chabaudi chabaudi.
..................................................................................................................................................
Proportion of CB and AJ in mixtures
used to induce the blood infections
No. of mosquitoes dissected
for oocysts (no. infected)
Average no. of
oocysts per gut
(SEM)
No. of mosquitoes
dissected for sporozoites
Predicted no. of
oocysts represented
Predicted no. of
recombinant lines
1:1 11 (8) 9.5 (9.26) 190 1,312 2,624
1:2 16 (7) 4.06 (3.96) 190 337 674
2:1 18 (13) 3.13 (6.02) 125 283 566
Total 45 (28) Total 505 Total 1,932 Total 3,864
The predicted number of such recombinants is calculated as described (see Materials and Methods). SEM, standard error of mean.
doi:10.1371/journal.pone.0000857.t001
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Figure 3. The Comparative Intensities of 92 AFLP markers of Plasmodium chabaudi chabaudi strain AJ from the progeny of a genetic cross
between P. c. chabaudi strains CB-pyr10 and AJ following selection in mice immunised strain AJ (see text). AJ-specific markers (indicated by black
diamonds) were located on a P. c. chabaudi genetic linkage map, generated from a genetic cross between AS and AJ [34]. Numbers after letter ‘C’ and
‘g’ represent P. c. chabaudi chromosome numbers and P. c. chabaudi unassigned linkage groups, respectively, in the genetic linkage map [34]. Of the
six AJ markers which were most reduced under AJ-specific immune selection (see Table 2), five (indicated by asterisks) could be located to P. c.
chabaudi chromosome 8, forming a selection valley with the P. c. chabaudi msp-1 gene at its lowest point (see text). RTQ-PCR values for the
proportions of the AJ-immune selected cross progeny carrying the AJ alleles of the Merozoite Surface Protein-1 (msp-1) are indicated by the red
triangle and Apical Membrane Antigen-1 (ama-1) by the green triangle in the AJ-immune selected cross progeny. The red line indicates Comparative
Intensity of 50%.
doi:10.1371/journal.pone.0000857.g003
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selection formed a linkage group that contains the gene encoding
the P. c. chabaudi AMA-1 (Table 2, Figure 3). An ama-1 strain
specific RTQ-PCR assay for CB and AJ (see Materials and Methods)
showed that 17.3% of the DNA of parasites in the AJ-immune
selected cross progeny carried the AJ allele of ama-1 (Table 2),
compared to 79.6% carrying the AJ allele of ama-1 in the cross
progeny grown in the non-immune mouse.
In a reciprocal experiment the uncloned progeny of the cross
between P. c. chabaudi strains CB and AJ were subjected to CB-
specific immune selection. The intensities of most of the AFLP
markers for strain CB (CB markers) were already very faint in the
unselected (control) cross progeny compared to the intensity of the
corresponding AFLP bands in the parental strain CB. The general
band intensities of the CB markers were below the limit of
detection by AFLP in the CB-immune selected cross progeny [35].
Consequently we were unable to achieve a meaningful analysis of
the CB-immune selected cross progeny by AFLP. We were,
nevertheless, able to investigate the level of CB-specific immune
selection against the CB allele at the msp-1 and ama-1 loci using
RTQ-PCR. In DNA from parasites of the CB-immune selected
cross progeny the CB allele of msp-1 was undetectable (,1%) by
RTQ-PCR, compared to 40.0% in the cross progeny grown in the
non-immune mouse. At the ama-1 locus, 1.8% of the DNA of
parasites carried the CB allele of ama-1 from cross progeny grown
in the CB-immunised mouse, compared to 20.4% in the cross
progeny grown in the non-immune mouse.
DISCUSSION
Linkage Group Selection is a molecular and genetic approach that
applies a specific selection pressure to the uncloned recombinant
progeny of a genetic cross between two genotypes (strains) of the
same species of malaria parasites that differ in their phenotypic
responses under the specified selection pressure [36,37]. Here we
have used LGS in an attempt to identify the region(s) in the
genome of the rodent malaria parasite Plasmodium chabaudi chabaudi
which contains the gene(s) for a target of SSPI against the blood
stages of this parasite. We have taken two genetically distinct
strains of P. c. chabaudi, CB and AJ, which induce SSPI with respect
to each other in laboratory mice, and crossed them to produce
recombinant progeny. We then applied SSPI selection to the
uncloned recombinant progeny by growing the cross progeny in
mice made immune to one or the other of the two strains of the
parasite (strain specific immunised mice). As a reference (LGS
control), the same uncloned progeny was also grown in a non-
immune batch mate of the strain specific immunised mice. The
cross progeny grown in the CB- or AJ-immunised mouse, or the
non-immune batch mate, was screened for the presence and
intensity of quantifiable genome-wide AFLP markers distinguish-
ing CB and AJ.
Following growth of the cross progeny in the AJ-immunised
mouse, a small proportion of markers of the immunising strain (AJ
markers) was judged to be significantly reduced (CI of ,50%)
relative to the progeny grown in the non-immune mouse. These
markers were located in the genome by either physical or genetic
mapping, or both, as described in Results. Several AJ markers that
were located to a region on P. c. chabaudi chromosome 8 formed
the deepest identified selection valley in this analysis (Figure 3).
Within this selection valley, the two AJ markers under the
strongest AJ-specific immune selection spanned a predicted
,120 kb region (based upon the predicted physical locations of
the orthologues of these two markers in the P. falciparum genome)
containing a gene for the P. c. chabaudi MSP-1, a principle
candidate for a target antigen of SSPI. RTQ-PCR analysis
confirmed that the uncloned cross progeny carrying the AJ allele
of the msp-1 gene was virtually eliminated after selection in the AJ-
immunised mouse. The reciprocal result was obtained after
selection of the cross progeny in a CB-immunised mouse. In this
case parasites carrying the CB allele of the P. c. chabaudi msp-1 locus
were virtually eliminated. These results demonstrate that parasites
carrying AJ or CB alleles in the region of the msp-1 locus were
under very strong selection in AJ- or CB-immunised mice,
respectively. A previous LGS analysis of SSPI in the progeny of
a genetic cross between strains AS-pyr1 and CB of P. c. chabaudi
also found that the region containing the msp-1 locus was under the
strongest detected strain specific protective immune selection for
this combination of strains [9]. Together, these results strongly
support the view that the region on P. c. chabaudi chromosome 8
around the msp-1 locus contains a gene or genes encoding a major
target antigen or antigens of SSPI.
In addition to those AJ markers associated with the
selection valley around msp-1, several other AJ markers had CIs
of less than 50% after selection in the AJ-immunised mouse
(Table 2, Figure 3), suggesting the possible presence of other
targets of SSPI.
Several of these more weakly reduced AJ markers formed
linkage groups having possible association with selection valleys.
One such group, containing seven affected AJ markers, was
located on P. c. chabaudi chromosome 7. This group spanned 62.3
centiMorgan (cM) by genetic mapping along chromosome 7, but
there was uncertainty as to the location of these markers in the
genome by physical mapping (see Table 2). Two other such
markers were located on P. c. chabaudi unassigned linkage groups 2
and 12 (Table 2). The reductions in intensity of all these markers
after selection in the AJ-immunised mouse were, however, much
less than those associated with the msp-1 locus, suggesting relatively
small contributions toward SSPI. No obvious candidate gene for
a target antigen of SSPI has been identified within these genomic
regions.
Three of the relatively weakly affected AJ markers were
located on P. c. chabaudi chromosome 9 and were linked to the
gene for AMA-1 (Table 2), another candidate target of SSPI [31].
The results suggest that AMA-1, or the product of a gene closely
linked to that for AMA-1, may be a target of SSPI, but one that is
less strongly affected than the target(s) associated with the gene for
MSP-1.
As already noted we had previously conducted LGS analysis of
SSPI with a combination of P. c. chabaudi strains, AS-pyr1 and CB
[9]. However, in contrast to the situation in the present cross
between AJ and CB, the AS-pyr1 and CB strains have DNA
sequences which are identical at the ama-1 locus for the
extracellular domain of the AMA-1 protein (Cheesman and
Carter, unpublished data). It is, therefore, highly unlikely that
evidence of the involvement of AMA-1 in SSPI could have been
found in the AS-pyr1 and CB cross, nor was it [9].
There is a possibility that there are other regions of the P. c.
chabaudi genome that may be under SSPI selection pressure but
have not been detected, as no AFLP markers have been mapped
on P. c. chabaudi chromosomes 2, 3, 4 and 14 and only a few on
chromosomes 10 and 12 (Figure 3). Nevertheless, quite large
chromosomally unassigned linkage groups (see Figure 3) were
identified. These almost certainly represent groups of linked
markers on all, or most, of the missing chromosomes [34]. Since
no clear selection valley has been located on any of these
unassigned linkage groups, it is unlikely that our analysis failed to
identify any other major SSPI-associated selection valleys that
might exist.
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progeny of two different genetic crosses, one between AJ and CB-
pyr10 (in this present study) and the other between AS-pyr1 and
CB (the parental clone of CB-pyr10) [9]. Both analyses have
revealed prominent selection valleys at the same location on P. c.
chabaudi chromosome 8. In both cases, the base of the SSPI-
selected valley covered a region within ,60 kb on either side of
the msp-1 locus. We conclude, therefore, that the P. c. chabaudi msp-
1 locus, or a gene very closely linked to it, dominated the SSPI
selection in both of these combinations of P. c. chabaudi strains.
Although our work has not yet proved that the P. c. chabaudi MSP-
1 protein is itself a target of SSPI in malaria, such a result would be
consistent with the literature that indicates the involvement of
MSP-1 in the strain specific protective immune response in the
rodent malarias. Thus, on passive transfer into non-immune mice,
monoclonal antibody (mAb) NIMP23, which had been raised
against the MSP-1 protein of P. c. chabaudi strain AS, inhibited the
growth of blood stages of the homologous strain (AS) [29], but had
no effect on a heterologous challenge infection with strain CB of P.
c. chabaudi [30]. Following these studies, McKean and colleagues
were able to identify an epitope to which mAb NIMP23 bound
and which was located at the C-terminus of P. c. chabaudi MSP-1
[38]. This part of MSP-1 was shown to be genetically distinct
between strains AS and CB ([39], Cheesman and Carter,
unpublished data). The MSP-1 sequence in the same region is
also different between strains AJ and CB ([39], Cheesman and
Carter, unpublished data), that are the two parental strains used in
the present LGS analysis of SSPI. However, between strains AS
and AJ, two strains which show virtually no SSPI with respect to
each other (Carter and Martinelli, unpublished data), there is no
difference in the amino acid sequence of MSP-1 in this region
[39]. The sequence polymorphisms identified at the C-terminus of
protein sequence within this region of MSP-1 in P. c. chabaudi are,
therefore, consistent with the involvement of MSP-1 in SSPI in
this parasite.
In conclusion, SSPI to blood stage malarial infections has been
observed in malarias of rodents [7,9,10]. Using LGS analyses, we
have identified a region on P. c. chabaudi chromosome 8 which is
under strong SSPI selection and which contains the gene for P. c.
chabaudi MSP-1. No other region in the P. c. chabaudi genome was
found to contain a similarly strong target of SSPI.
MATERIALS AND METHODS
Parasites, Laboratory Mice and Mosquitoes
Two cloned strains of the rodent malaria species P. c. chabaudi
denoted CB-pyr10 and AJ were used in these experiments. CB-
pyr10 is a pyrimethamine resistant cloned line derived through
pyrimethamine selection from CB (a pyrimethamine sensitive line),
originally cloned from isolate CB [40]. In this study, CB-pyr10 will
be referred to as CB for simplicity. AJ is a pyrimethamine sensitive
line, cloned from isolate AJ [18]. Both cloned lines are known to
be genetically distinct from each other [18]. AJ and CB were
isolated from wild thicket rats, Thamnomys rutilans, captured in the
same locality in the Central African Republic in 1969 and 1970,
respectively [17,41]. Maintenance of the parasite lines is described
in detail elsewhere [10].
Females of inbred laboratory mouse strains, CBA/Ca and
C57BL/6J, were used, aged 5 to 6 weeks old on first infection.
These mouse strains will be referred here to as CBA and C57.
Mosquitoes were from a laboratory-bred colony of Anopheles
stephensi. Mice and mosquitoes were maintained as previously
described [42,43]. All animal work in this study was carried out in
accordance with the Animals (Scientific Procedures) Act 1986 UK.
Induction and characterisation of SSPI between
cloned strains CB and AJ of P. c. chabaudi
Immunity was induced in groups of CBA mice by two consecutive
rounds of infection with P. c. chabaudi followed by mefloquine cure
with slight modifications from the method previously described
[10]. In brief, each experimental mouse was inoculated intra-
peritoneally (i.p.) with 5610
5 pRBC of either strain, CB or AJ, of
P. c. chabaudi. Blood stage malarial infections were terminated by
four consecutive daily doses of 20 mg/kg mouse body weight of
mefloquine in 0.1 ml Dimethyl Sulfoxide, by oral gavage.
Mefloquine treatment started before parasitaemias exceeded
50% but after they had passed 20% of infected red blood cells.
The blood stage parasites were monitored daily by microscopic
examination of thin blood smears stained with Giemsa’s stain.
Following each mefloquine treatment all mice remained blood
smear negative. Twenty-six days after the last day of the first
mefloquine treatment, mice were given a second i.p. infection with
5610
6 pRBC of the P. c. chabaudi strain homologous to the first
immunising one. Infections were grown for 5 days and drug cure
treated as before.
Sixteen weeks after the second mefloquine treatment, two mice
previously immunised by blood stage parasite infection with either
CB or AJ from each group were randomly chosen to test for the
presence of SSPI. Each mouse was challenged with a mixture of
5610
6 pRBC containing an equal proportion of blood stage
parasites, CB and AJ. An equivalent inoculum from the same
mixture was inoculated into a non-immune mouse, which was
a batch mate of the immunised mice. The resulting infections were
examined daily by microscopic analysis. A 20 ml sample of tail
blood in physiological citrate saline (0.85% (w/v) sodium chloride,
1.5% (w/v) tri sodium citrate dihydrate, in distilled water, adjusted
to pH 7.2 with hydrochloric acid) was collected from each mouse
5–8 days post infection, so as to accurately measure proportions of
parasites of each strain (CB and AJ) using strain specific RTQ-
PCR for CB and AJ alleles of the msp-1 gene [10,44]. Tail blood
samples were spun at 5,000 rpm for 3 minutes. The red blood cell
pellet was washed with 200 ml phosphate buffered saline (Sigma)
and stored at 270uC prior to DNA extraction using a High Pure
PCR template preparation kit (Roche Diagnostics). RTQ-PCR
analysis was performed as previously describe by the method of
Cheesman et al., [10,44].
Preparation of a Genetic Cross between Cloned
Strains CB and AJ of P. c. chabaudi
Single strain infections with CB and AJ were individually grown in
donor C57 mice. Parasites of the two strains were harvested from
the donors and accurately mixed to produce three inocula in
proportions of 1:1, 1:2 and 2:1 of CB and AJ, respectively. The
mixtures were inoculated i.p. at 10
6 pRBC per mouse into three
groups of C57 mice (four mice each). The parasitaemias from the
mixed strain infections were followed microscopically on thin tail
blood smears stained with Giemsa’s stain. Six days post
inoculation of the parasites, when parasitaemias were ,20%
and the presence of gametocytes of both sexes was confirmed
microscopically, mice from each mixed strain infection group were
anaesthetised and placed on a mosquito cage, each containing
,250 female mosquitoes. Mosquitoes were aged 5–7 days post
emergence from pupae. The mosquitoes were allowed to feed on
the mice for 20 minutes without interruption. The mice were
thereafter humanely killed before recovery from the anaesthesia.
Eight days after the blood meal, samples of mosquitoes from each
cage were dissected and examined for the presence of oocysts on
their midguts. 11 mosquitoes from those fed on the 1:1 CB:AJ
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Mean, SEM=9.26); 16 mosquitoes from those fed on the 1:2
CB:AJ mixture had a mean of 4.06 oocysts per gut (SEM=3.96);
18 mosquitoes from those fed on the 2:1 CB:AJ mixture had
a mean of 3.13 oocysts per gut (SEM=6.02).
Sixteen days after the blood meal, when sporozoites were
present in the mosquito salivary glands, the mosquitoes were
allowed to feed on 6 non-immune CBA female mice in order to
naturally transmit sporozoites of the progeny of the CB6AJ
genetic crosses. All surviving mosquitoes of these three batches
were then dissected for sporozoites from the salivary glands (190
mosquitoes from the 1:1 CB:AJ mixture, 190 mosquitoes from the
1:2 CB:AJ mixture and 125 mosquitoes from the 2:1 CB:AJ
mixture). The glands were gently crushed in 0.2–0.4 ml volumes of
1:1 Foetal Bovine Serum (GIBCO BRL): Ringer’s solution
(2.7 mM Potassium Chloride, 1.8 mM Calcium Chloride,
154 mM Sodium Chloride) and injected i.p. into 8 non-immune
CBA mice. All 14 mice, naturally infected or inoculated with
sporozoites dissected from salivary glands of the mosquitoes,
became infected. The blood stage parasites representing the
progeny of the genetic cross were harvested on day 9 post infection
(mean parasitaemia=15%, min=0.6% and max 61%) and
pooled prior to inoculation of mice previously immunised with
parasites of either one or the other of the parental strains CB or AJ
for SSPI selection, or else into a non-immune batch mate. The
remaining pooled blood was frozen as stabilates and stored in
liquid nitrogen.
From the data on the number of oocysts per mosquito and the
number of mosquitoes dissected for inoculation of sporozoites
(given above), it is possible to estimate the likely maximum
numbers of recombinant lines that a genetic cross could have
generated. On an assumption that gametes of the two parasite
strains are generated in equal numbers in the mixed strain
infection used to make a genetic cross, and that fertilisations occur
randomly between them, half of all fertilisations will generate
hybrid zygotes between the gametes of the two parental strains of
parasite, while the second half will derive equally from the self
fertilisations representing one or other of the two parental strains.
Each hybrid zygote undergoes meiosis and produces four
recombinant progeny lines. Thus, on average, for every four
oocysts in such a genetic cross, there will be two parental and two
hybrid oocysts, yielding a total of eight recombinants. Overall,
therefore, there are, on average, two recombinant lines for every
oocyst present. Using this logic we were able to estimate the likely
maximum number of recombinant lines present in the pooled
cross progeny (Table 1).
SSPI Selection of Uncloned Cross Progeny for
Linkage Group Selection Analysis
The blood stage parasites from a total of 14 non-immune CBA
mice (six and eight mice from the natural transmission and the
sporozoite-induced infection, respectively) were harvested in
physiological saline and pooled to produce the blood inoculum
containing the uncloned CB6AJ cross progeny. One mouse from
the batches immunised with blood stage parasite of either CB or
AJ and previously tested for SSPI to these strains was inoculated
i.p. with 5610
6 pRBC of the uncloned cross progeny. At time of
infection with the cross progeny, the immunised mice were twenty
weeks after the last day of the second mefloquine treatment (see
above). The blood stage parasites from the cross progeny grown in
these mice which had been previously immunised with CB or AJ,
were designated ‘‘CB-immune selected cross progeny’’ or ‘‘AJ-
immune selected cross progeny’’, respectively. An equal number of
the cross progeny designated ‘‘non-immune selected cross
progeny’’ was passaged into a non-immune batch mate of the
immunised mice. The resulting infections were followed by
microscopic examination of thin blood smears stained with
Giemsa’s stain. The uncloned cross progeny was grown in the
CB- and AJ-immunised mice for 11 and 12 days, respectively. In
the non-immune batch mate, the cross progeny was allowed to
grow for 9 days. To grow parasites in sufficient quantities to
prepare DNA for subsequent analysis, blood was, thereupon,
collected, and 10
6 pRBC from each mouse were inoculated into
four non-immune mice. The parasites were grown in these mice to
parasitaemias of ,35–50% before harvesting and preparing them
for DNA extraction, as previously described by Grech et al., [32].
Quantitative Measurement of Strain Specific
Amplified Fragment Length Polymorphism (AFLP)
Markers
To locate regions of the P. c. chabaudi genome affected by the SSPI
selection, we generated
33P-radiolabelled AFLP markers from
genomic DNA of the CB- and AJ-immune selected cross progeny,
thenon-immune selectedcross progenyand the two parental cloned
strains (CB and AJ) by the method of Grech et al., [32]. AFLP
products were resolved on 6% denaturing polyacrylamide gel
electrophoresis and visualised using a Phosphoscreen (Amersham)
and an X-ray film (Kodak). The intensities of AFLP bands were
quantitatively measured using ImageQuant
TM software version 1.2
Build 039 (Molecular Dynamics), as described by Martinelli et al.,
[35]. For the purpose of determining the proportions of the parasite
population carrying a specific allele for CB or AJ represented by
individual AFLP markers in the immune and non-immune selected
materials, we calculated a ‘‘Relative Intensity Index (RII)’’. This is
defined as the intensity of the strain specific AFLP marker band in
the mixture divided by the intensity of a designated non-
polymorphic band in the same mixed parasite sample, divided by
the equivalent ratio of the two relevant bands (strain specific AFLP
and non-polymorphic band) measured in a sample of the pure
parental strain [35]. The RII of parasites bearing specific AFLP
markers for CB and AJ in the immune selected cross progeny (RIIi)
were, thereafter, quantitatively compared to the RII of the same
markers derived from the non-immune selected cross (RIIni). These
proportions were, then, used to calculate the ‘‘Comparative
Intensity (CI)’’- a measurement of proportional changes of strain
specific AFLP markers between the immune and non-immune
selected cross progeny. The CI is defined by the RII of a strain
specific AFLP marker of the immune-selected cross progeny (RIIi)
divided by the RII of the relevant marker of the non-immune
selected cross progeny (RIIni), and expressed as a percentage, i.e.,
CI=(RIIi/RIIni)6100 [9]. Specific AFLP markers of the immunis-
ing parasite strain whose CI values were less than 50% were
considered to be under SSPI selection [9].
Physical and Genetic mapping of AFLP markers
under SSPI selection
Strain specific AFLP markers that had CI reduced below 50%
following the strain specific immune selection were identified and
characterised by the methods of Hunt et al., [45] and Martinelli et
al., [9]. The physical location of AFLP markers under SSPI
selection was conducted as follows. Individual AFLP markers were
excised and eluted from the polyacrylamide gel into distilled water
to obtain DNA fragments of each marker. The extracts were PCR
amplified using the same pairs of AFLP primers and conditions
that were used to generate the original AFLP markers [32]. PCR
Targets of Malaria Immunity
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AFLP primers. The sequencing reactions used ABI BigDye
Terminator Chemistry on ABI3700 sequencing machine, accord-
ing to manufacturer’s instructions. For PCR products of AFLP
markers less than 100 bp, DNA sequences were obtained by
cloning with a TOPO TA cloning kit
TM (Invitrogen). Plasmid
DNA from each transformed colony was extracted using
a QIAprep Spin Mini Prep kit (QIAGEN) and sequenced as
described above. DNA sequences obtained from the forward and
reverse primers were visualised using an EditView ABI automated
DNA sequence viewer software (Perkin Elmer ABI) and assembled
manually to generate a single contiguous sequence. The sequences
of the specific AFLP primers were eliminated from the assembled
DNA sequence prior to location of the AFLP marker onto the
genome databases by BLAST search.
Eight-fold coverage contigs of the genome of P. c. chabaudi
cloned strain AS, http://www.sanger.ac.uk/cgi-bin/blast/submit-
blast/p_chabaudi, were searched using the BLASTN (DNA vs.
DNA) option with sequences derived from the AFLP markers.
Genomic contigs of P. c. chabaudi which contained DNA sequences
corresponding to the relevant AFLP marker with lowest
Probability score (a cut-off of 90% sequence identity) were
obtained. The chromosomal positions of these contigs have not
been mapped physically in the P. c. chabaudi genome. Sequences of
whole P. c. chabaudi contigs were, thereafter, used to locate
orthologous loci in the Plasmodium falciparum (cloned strain 3D7)
genome database [46] (http://www.ncbi.nlm.nih.gov/sutils/blas-
t_table.cgi?taxid=Protozoa&database), using the blastn option.
The genomic locations of the P. falciparum orthologues were, in
turn, used for physical mapping to chromosomal locations in the
genome of P. c. chabaudi through the conserved genetic synteny
between the human malaria parasite P. falciparum and rodent
malaria parasites [33].
In addition to physical mapping, the strain specific AFLP
markers were genetically located on a P. c. chabaudi genetic linkage
map which was constructed with reference to the progeny of
a genetic cross between P. c. chabaudi strains AS and AJ (see [34] for
the method).
RTQ-PCR of CB and AJ alleles of P. c. chabaudi msp-1
and ama-1
RTQ-PCR analysis was performed on a LightCycler instrument
(Roche Diagnostics) as described by Cheesman et al., [10,44] for
allele specific amplification assays to measure in the mixtures of
parasites the proportions of DNA of the CB or AJ allele of the msp-
1o rama-1 gene. The assays have been standardized for accurate
quantification of the CB or AJ alleles of msp-1 or ama-1 of the blood
stage parasites, using artificial mixtures with known proportions of
cloned strains CB and AJ as previously described by Cheesman et
al., [44]. DNA samples of (i) the blood stage mixed strain infections
and (ii) the uncloned CB x AJ cross progeny grown in the strain
specific immunised and non-immune mice were prepared as
described in previous sections. DNA samples of the pure parental
strains CB and AJ were 10-fold serially diluted in the range 66-
0.0066 ng and used as quantification standards to construct a DNA
concentration calibration curve. Oligonucleotide primers were
designed to selectively amplify a strain specific region of the msp-1
or ama-1 gene (Cheesman and Carter, unpublished data). The msp-
1 specific primers used in the assay were: the CB forward and
reverse primers: 59-AGTTGTTCCTGTGGCAG-39 and 59-
CTGTTACAACCCAAACC-39; and the AJ forward and reverse
primers: 59-ACTGAAGCAACAACACCAGC-39 and 59-GTTG
TTGATGCACTTGCGGGTTC-39. RTQ-PCR reactions for the
CB and AJ alleles of msp-1 were set up, as previously described
[10]. The ama-1 specific primers used in the assay were: the CB
forward and reverse primer 59-AGGTTTCATTATTAACAC-
GAG-39 and 59-GATTACTTTTGTC ATAAACAGCG-39; and
the AJ forward and reverse primer 59 CTAAATCATTCTTAGA
CCC-39 and 59-GGCATAATTTTTATATTCTG-39. The posi-
tions at which nucleotides of the CB and AJ ama-1 alleles
mismatched are shown in bold. RTQ-PCR reactions for
quantification of the CB and AJ alleles of ama-1 were performed
in a 10 ml volume of standard buffer containing 4 mM of forward
and reverse primers in 3 and 2.5 mM MgCl2, respectively. The
PCR conditions used were as follows: An initial ‘‘Hot Start’’ at
95uC for 600 s followed by 40 cycles of 95uC with a 0 s hold,
cooling at 20uC/s to 58uC with a 7 s hold for CB or cooling at
20uC/s to 56uC with a 7 s hold for AJ, reheating at 20uC/s to
72uC with a 15 s hold for CB or 10 s hold for AJ and finally
heating at 20uC/s to 72uC with a 0 s hold. Melting curve data for
each PCR run was produced, as follows: Heating at 20uC/s to
95uC with 0 s hold, cooling at 20uC/s to 65uC with 30 s hold and
reheating at 0.2uC/s to 95uC in a continuous data acquisition
mode. The final step of RTQ-PCR was at 20uC/s to 40uC with
a 60 s hold. Data obtained from each LightCycler run were
checked to ensure that the correct strain specific melting peak and
no other non-specific amplicon was produced. The DNA
concentrations measured on the LightCycler were converted into
relative proportions of the AJ and CB alleles for msp-1 or ama-1
within each sample analysed.
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